Netherlands· NL-8ee4be8940a7
Esmolol HCl Hikma 10 mg/ml, oplossing voor injectie
A esmolol product containing esmololhydrochloride, registered in Netherlands by Hikma Farmaceutica (Portugal), S.A.. The same ATC class is registered in 16 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Esmolol is registered in 16 of 19 countries.
Countries holding a registration under ATC C07AB09 (esmolol), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Esmolol · ATC C07AB09
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ESMOLOLHYDROCHLORIDE
- Manufacturer
- Hikma Farmaceutica (Portugal), S.A.
- Country
- Netherlands (NL)
- ATC code
- C07AB09
- ATC class
- Esmolol
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id116724
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
196 interactions on record for esmolol.
Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Esmolol · interactions on record
196 records
- 11 severe
- 139 moderate
- 8 minor
Most severe, free to view
- DolasetronA04AA04severe
- TheophyllinC01EB28severe
- CeritinibL01ED02severe
- CeritinibL01XE28severe
38 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Esmolol in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceBREVIBLOC 10 mg/ml, solution pour perfusionBAXTER
- United StatesBreviblocBaxter Healthcare Company
- United KingdomBrevibloc Concentrate 2.5g/10ml solution for infusion ampoulesBaxter Healthcare Ltd
- FinlandBreviblocBaxter Oy
- GermanyBreviblocBaxter Deutschland Gmbh
- SwitzerlandBrevibloc 100 mg, InjektionslösungBaxter AG
- SpainBREVIBLOC 10 mg/ml SOLUCION INYECTABLEBaxter S.L.
- BelgiumBrevibloc 10 mg/mlBaxter
Authorised across Europe · EMA
The same active substance is authorised in 21 EEA countries. Names it is sold under:
- Austria · Brevibloc, Esmolol Amomed
- Belgium · Brevibloc
- Cyprus · Brevibloc, Esmobeta
- Czechia · Esmocard, Esmocard Lyo
- Germany · Brevibloc, Esmocard
- Denmark · Brevibloc
- Spain · Brevibloc, Esmolol Aurovitas
- Finland · Brevibloc
- France · Brevibloc, Esmocard
- United Kingdom (Northern Ireland) · Brevibloc Premixed, Esmolol Hikma Farmacêutica (Portugal)
- Greece · Brevibloc, Esmobeta
- Croatia · Esmocard
- Ireland · Brevibloc Premixed
- Italy · Brevibloc, Esmocard
- Luxembourg · Brevibloc
- Malta · Brevibloc Premixed
- Norway · Brevibloc
- Portugal · Brevibloc, Esmolol Eugia
- Sweden · Brevibloc
- Slovenia · Esmocard, Esmocard Lyo
- Slovakia · Esmocard, Esmocard Lyo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/68f24a75-ce84-4d82-93b2-95e954d89146 GET /v1/drugs/68f24a75-ce84-4d82-93b2-95e954d89146?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Intraveneus gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h116724_smpc.pdf",
"strength": null,
"atc_label": "Esmolol",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg116724",
"excipients": [
"AZIJNZUUR (E 260), GECONCENTREERD",
"NATRIUMACETAAT 3-WATER (E 262)",
"NATRIUMHYDROXIDE (E 524)",
"WATER VOOR INJECTIE",
"ZOUTZUUR (E 507)"
],
"substances": [
"ESMOLOLHYDROCHLORIDE"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h116724.pdf",
"authorised_at": "2016/10/18",
"procedure_number": "PT/H/1403/001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "116724",
"additional_monitoring": "N"
}See everything about esmolol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.